

AVGEMSI™

(gemcitabine) Injection

BILLING & CODING GUIDE

If you have additional billing and coding questions, please call your Field Reimbursement Manager or AVYXASSIST™ at 866-939-8927. Our Patient Access Specialists are available to assist Monday through Friday, 8 AM to 8 PM ET.

Please see Important Safety Information on pages 3 and 15-16 and full [Prescribing Information](#) for AVGEMSI™.



TABLE OF CONTENTS

Indications and Important Safety Information	3, 15-16
AVGEMSI™ Ordering Information	4
AVYXASSIST™ Patient Support Program	5
AVGEMSI™ Billing and Coding Information	6-10
NDCs	6
HCPCS Codes	6
J-Code Billing Unit Conversion	6
CPT Drug Administration Codes	7
Revenue Codes	7
ICD Diagnosis Codes	7-8
ICD Diagnosis Codes by Indication	8-10
Sample Claim Form CMS-1450 (UB-04)	11-12
Sample Claim Form CMS-1500	13-14
Important Safety Information (Continued)	15-16
Notes	17

The contents herein provide general coverage, coding, and payment information about AVGEMSI™ (gemcitabine) injection. The information within this guide was obtained from third-party sources and is made available for reference only. It is not exhaustive, is subject to change, and does not constitute billing, coding, or legal advice. Healthcare professionals are responsible for determining which code(s), charge(s), or modifier(s), if any, appropriately reflect a service or diagnosis. It is the healthcare professional's responsibility to determine medical necessity and provide adequate documentation. AVYXA™ does not guarantee coverage or payment. Payment and coverage vary by payer. Questions about coding, coverage, and payment may be directed to the applicable third-party payer, reimbursement specialist, and/or legal counsel.

CMS: Centers for Medicare & Medicaid Services; CPT: Current Procedural Terminology; HCPCS: Healthcare Common Procedure Coding System; ICD: International Classification of Diseases; NDC: National Drug Code

Please see Important Safety Information on pages 3 and 15-16 and full [Prescribing Information](#) for AVGEMSI™.

INDICATIONS AND IMPORTANT SAFETY INFORMATION

INDICATIONS

Ovarian Cancer

AVGEMSI™ in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy.

Breast Cancer

AVGEMSI in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated.

Non-Small Cell Lung Cancer

AVGEMSI in combination with cisplatin is indicated for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC).

Pancreatic Cancer

AVGEMSI is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. AVGEMSI is indicated for patients previously treated with fluorouracil.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATION

AVGEMSI is contraindicated in patients with a known hypersensitivity to gemcitabine. Reactions include anaphylaxis.

WARNINGS AND PRECAUTIONS

Schedule-Dependent Toxicity: In clinical trials evaluating the maximum tolerated dose of gemcitabine, prolongation of the infusion time beyond 60 minutes or more frequent than weekly dosing resulted in an increased incidence of clinically significant hypotension, severe flu-like symptoms, myelosuppression, and asthenia. The half-life of gemcitabine is influenced by the length of the infusion.

Myelosuppression: Myelosuppression manifested by neutropenia, thrombocytopenia, and anemia, occurs with gemcitabine as a single agent and the risks are increased when gemcitabine is combined with other cytotoxic drugs. In clinical trials, Grade 3-4 neutropenia, anemia, and thrombocytopenia occurred in 25%, 8%, and 5%, respectively of the 979 patients who received single agent gemcitabine. The frequencies of Grade 3-4 neutropenia, anemia, and thrombocytopenia varied from 48% to 71%, 8% to 28%, and 5% to 55%, respectively, in patients receiving gemcitabine in combination with another drug.

Prior to each dose of AVGEMSI, obtain a complete blood count (CBC) with a differential and a platelet count. Modify the dosage as recommended.

Severe Cutaneous Adverse Reactions (SCARs): SCARs, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP), which can be life-threatening or fatal, have been reported in association with gemcitabine treatment. Monitor patients for signs and symptoms of severe cutaneous adverse reactions. Permanently discontinue gemcitabine in patients who develop SCARs.

AVGEMSI™ (gemcitabine) Injection

Ordering Information

To order AVGEMSI™ (gemcitabine) injection, please contact one of these authorized specialty distributors and use the appropriate order number:



1 g/26.3 mL
NDC: 83831-0123-01

2 g/52.6 mL
NDC: 83831-0124-01

Institutions/Hospitals	1 g/26.3 mL	2 g/52.6 mL
Cardinal Health Specialty	6044630	6044648
CENCORA - ASD Healthcare	10301985	10301983
McKesson Plasma & Biologics	3048402	3048428
Physician Offices	1 g/26.3 mL	2 g/52.6 mL
Cardinal Health Specialty	6044630	6044648
Oncology Supply	10301906	10301908
McKesson Specialty Health	5020581	5020582

Highlights

- Supplied in multiple-dose vials as 1 g/26.3 mL and 2 g/52.6 mL
- Free from mannitol, sodium acetate, and hydrochloric acid
- No reconstitution required
- Partially used multiple-dose vials are stable for up to 14 days when stored in the original cartons refrigerated at 2°C to 8°C (36°F to 46°F)
- Ready to add to intravenous infusion solution with 0.9% Sodium Chloride Injection, USP

UNIQUE
J-CODE

J9184

Effective January 1, 2026



Simplifying Patient Access, Providing Comprehensive Support.

AVYXASSIST™ can offer support to qualifying patients in need. The program provides the following services*

- Benefit verification
- Prior authorization requirements
- Appeals process information
- Claims Support
- Referrals to 501(c)(3) foundations when applicable
- Free product assistance (uninsured or underinsured)
- Bridge supply (coverage delays)
- Product replacement
- Copay assistance

COPAY ASSISTANCE PROGRAM

Eligible patients prescribed an AVYXA product may pay as little as

\$ 0 per dose*

TO ENROLL, PLEASE CHOOSE ONE OF THE FOLLOWING OPTIONS



Phone

866-939-8927
Monday through Friday
8 AM to 8 PM ET

[CALL NOW](#)



Online

Click on the link below to begin your online enrollment

[ENROLL NOW](#)



Fax

Download, print and fax the completed enrollment form to 833-852-3420

[DOWNLOAD NOW](#)

OR

OR

*For eligibility requirements, please contact a Patient Access Specialist. Terms and conditions apply.

AVGEMSI™ Billing and Coding Information

The information provided is for informational purposes only and represents no statement, promise, or guarantee by AVYXA™ concerning reimbursement, payment, or charges. The information provided is not intended to increase or maximize reimbursement by any payer. Healthcare professionals are responsible for selecting appropriate codes used to file a claim. Codes should be based on the patient's diagnosis and the items and services furnished by the healthcare professional. All codes should be verified between the healthcare professional and the payer. AVYXA™ does not recommend using any particular diagnosis code in billing situations for AVGEMSI™ (gemcitabine) Injection. The below codes are for reference only; coding as submitted is the sole responsibility of the prescribing physician.

NDCs

AVGEMSI™ NDC ¹	Strength	Package	NDC Unit
83831-0123-01	1 g/26.3 mL (38 mg/mL)	1 multiple-dose vial in 1 carton	mL
83831-0124-01	2 g/52.6 mL (38 mg/mL)	1 multiple-dose vial in 1 carton	mL

Nearly all drugs in the United States are assigned a unique National Drug Code (NDC), which identifies all currently manufactured drugs and is maintained by the U.S. Food and Drug Administration (FDA). NDCs are sometimes packaged with fewer than 11 digits—some have fewer than 10. However, for billing purposes, the NDC must be reported in the 11-digit 5-4-2 format, as shown above.

HCPCS Code

HCPCS Level II codes are used to identify most drugs and biologics administered in the office².

AVGEMSI™ Unique J-Code	Description
J9184	Injection, gemcitabine hydrochloride (avyxa), 200 mg

Note: While there are several HCPCS codes associated with gemcitabine products, **AVGEMSI™** is assigned a unique HCPCS code (**J9184**). Please ensure the HCPCS code used matches the specific product purchased and administered.

J-Code Billing Unit Conversion

Example:

AVGEMSI™ is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. AVGEMSI™ is indicated for patients who have previously received treatment with fluorouracil³.

The recommended dosage of AVGEMSI™ is 1,000 mg/m² intravenously over 30 minutes⁴. An individual with a body surface area of 1.9 m² receives 1900 mg of AVGEMSI™ in over 30 minutes. The service unit for J9184 is 200mg. Service units must be rounded to whole numbers. In this example, 2000mg is billed as 10 units.

CPT Drug Administration Codes

CPT codes are used to bill drug administration services in the physician's office and other outpatient settings.⁵ AVGEMSI™ has a 30-minute intravenous infusion time for differing indications. However, please code according to the start and stop times listed in the patient's medical chart.⁶ Please schedule patients to ensure minimal disposal. AVGEMSI™ is supplied as a multiple-dose vial. Medicare will not pay for drug waste on multiple-dose vials, so the JW and JZ modifiers are not applicable in the billing of AVGEMSI™.⁷

CPT Code	Description	Place of Service (POS) ⁸
96413	Chemotherapy administration, intravenous infusion technique, up to 1 hour, single or initial substance drug ⁹	<ul style="list-style-type: none">Physician Office (11)Off-Campus Outpatient Hospital (19)On-Campus Outpatient Hospital (22)
96417	Chemotherapy administration, intravenous infusion technique, each additional sequential infusion (different substance/drug), up to 1 hour ¹⁰	

CPT codes, descriptions, and other data only are copyright 2022 American Medical Association. All Rights Reserved. Applicable FARS/HHSARS apply. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

Revenue Codes

Claim Item	Revenue Code	Description	Place of Service (POS)
AVGEMSI™	0636	Drugs Requiring Detailed Coding ¹¹	<ul style="list-style-type: none">Off-Campus Outpatient Hospital (19)On-Campus Outpatient Hospital (22)
Drug Administration	0335	Chemotherapy Administration – IV ¹²	

ICD Diagnosis Codes

AVGEMSI™ is a nucleoside metabolic inhibitor indicated:

- in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy.
- in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated.
- in combination with cisplatin, for the treatment of non-small cell lung cancer.
- as a single agent for the treatment of pancreatic cancer.¹³

Please use the code for the cancer that is being treated with AVGEMSI™. Denials can be avoided if the most specific code is used for the AVGEMSI™ indication treated at each encounter. We have listed specific codes below.

International Classification of Disease, 10th Edition, Clinical Modification Codes for AVGEMSI™

Indication	ICD-10-CM Codes
Ovarian Cancer ¹⁴	C56.1, C65.2, C56.3, C56.9
Breast Cancer ¹⁵	C50.011, C50.012, C50.019, C50.021, C50.022, C50.029, C50.111, C50.112, C50.119, C50.121, C50.122, C50.129, C50.211, C50.212, C50.219, C50.221, C50.222, C50.229, C50.311, C50.312, C50.319, C50.321, C50.322, C50.329, C50.411, C50.412, C50.419, C50.421, C50.422, C50.429, C50.511, C50.512, C50.519, C50.521, C50.522, C50.529, C50.611, C50.612, C50.619, C50.621, C50.622, C50.629, C50.811, C50.812, C50.819, C50.821, C50.822, C50.829, C50.911, C50.912, C50.919, C50.921, C50.922, C50.929
Non-Small Cell Lung Cancer ¹⁶	C33, C34.00, C34.01, C34.02, C34.10, C34.11, C34.12, C34.2, C34.30, C34.31, C34.32, C34.80, C34.81, C34.82, C34.90, C34.91, C34.92
Pancreatic Cancer ¹⁷	C25.0, C25.1, C25.2, C25.3, C25.4, C25.7, C25.8, C25.9

ICD Diagnosis Codes by Indication

ICD-10-CM coding for AVGEMSI™ Injection varies greatly by payer. Please check with each payer to ascertain the best coding for AVGEMSI™ Injection according to their policy.

Ovarian Cancer: ICD-10-CM Diagnosis Coding

ICD-10 Code	Descriptor
C56.1	Malignant neoplasm of right ovary
C56.2	Malignant neoplasm of left ovary
C56.3	Malignant neoplasm of bilateral ovaries
C56.9	Malignant neoplasm of unspecified ovary

Breast Cancer: ICD-10-CM Diagnosis Coding

ICD-10 Code	Descriptor
C50.011 - C50.019	Malignant neoplasm of nipple and areola, female
C50.021 - C50.029	Malignant neoplasm of nipple and areola, male
C50.111 - C50.119	Malignant neoplasm of central portion of breast, female
C50.121 - C50.129	Malignant neoplasm of central portion of breast, male
C50.211 - C50.219	Malignant neoplasm of upper-inner quadrant of breast, female

Breast Cancer: ICD-10-CM Diagnosis Coding

ICD-10 Code	Descriptor
C50.221 - C50.229	Malignant neoplasm of upper-inner quadrant of breast, male
C50.311 - C50.319	Malignant neoplasm of lower-inner quadrant of breast, female
C50.321 - C50.329	Malignant neoplasm of lower-inner quadrant of breast, male
C50.411 - C50.419	Malignant neoplasm of upper-outer quadrant of breast, female
C50.421 - C50.429	Malignant neoplasm of upper-outer quadrant of breast, male
C50.511 - C50.519	Malignant neoplasm of lower-outer quadrant of breast, female
C50.521 - C50.529	Malignant neoplasm of lower-outer quadrant of breast, male
C50.611 - C50.619	Malignant neoplasm of axillary tail of breast, female
C50.621 - C50.629	Malignant neoplasm of axillary tail of breast, male
C50.811 - C50.819	Malignant neoplasm of overlapping sites of breast, female
C50.821 - C50.829	Malignant neoplasm of overlapping sites of breast, male
C50.911 - C50.919	Malignant neoplasm of breast of unspecified site, female
C50.921 - C50.929	Malignant neoplasm of breast of unspecified site, male

Non-Small Cell Lung Cancer: ICD-10-CM Diagnosis Coding

ICD-10 Code	Descriptor
C33	Malignant neoplasm of trachea
C34.00	Malignant neoplasm of unspecified main bronchus
C34.01	Malignant neoplasm of right main bronchus
C34.02	Malignant neoplasm of left main bronchus
C34.10	Malignant neoplasm of upper lobe, unspecified bronchus or lung
C34.11	Malignant neoplasm of upper lobe, right bronchus or lung
C34.12	Malignant neoplasm of upper lobe, left bronchus or lung
C34.2	Malignant neoplasm of middle lobe, bronchus or lung
C34.30	Malignant neoplasm of lower lobe, unspecified bronchus or lung

Non-Small Cell Lung Cancer: ICD-10-CM Diagnosis Coding

ICD-10 Code	Descriptor
C34.31	Malignant neoplasm of lower lobe, right bronchus or lung
C34.32	Malignant neoplasm of lower lobe, left bronchus or lung
C34.80	Malignant neoplasm of overlapping sites of unspecified bronchus and lung
C34.81	Malignant neoplasm of overlapping sites of right bronchus and lung
C34.82	Malignant neoplasm of overlapping sites of left bronchus and lung
C34.90	Malignant neoplasm of unspecified part of unspecified bronchus or lung
C34.91	Malignant neoplasm of unspecified part of right bronchus or lung
C34.92	Malignant neoplasm of unspecified part of right bronchus or lung

Pancreatic Cancer: ICD-10-CM Diagnosis Coding

ICD-10 Code	Descriptor
C25.0	Malignant neoplasm of head of pancreas
C25.1	Malignant neoplasm of body of pancreas
C25.2	Malignant neoplasm of body of pancreas
C25.3	Malignant Neoplasm of pancreatic duct
C25.4	Malignant neoplasm of endocrine pancreas
C25.7	Malignant neoplasm of other parts of pancreas
C25.8	Malignant neoplasm of overlapping sites of the pancreas
C25.9	Malignant neoplasm of pancreas, unspecified

Sample Claim Form CMS-1450 (UB-04)

Form Locator (FL) 42

(Electronic Claim Form = Loop 2400, Segment Type SV201):

List the appropriate revenue code for the drug. Match the descriptor for AVGEMSI™ injection to your revenue code, 0636 in the FL descriptor.

Additionally, enter an appropriate revenue code for the administration service, such as 0335 for chemotherapy administration - IV or others based on the cost center where the service was performed.

FL 43

(NOT REQUIRED BY MEDICARE):

Enter the description of the procedure for the Revenue Code billed.

If required, list the N4 indicator first, then the 11-digit NDC code. In the third place, list the NDC unit measurement code and, last, the quantity. Check with other payers for their requirements. The NDC Unit of Measurement for AVGEMSIT™ is ML.

FL 44

**(Electronic Claim Form = Loop
2400, SV202-2 (SV202-1=HC/HP):**

Enter the appropriate HCPCS code: **J9184, Injection, gemcitabine hydrochloride (avyxa), 200 mg.**

For administration, enter the appropriate code or codes for intravenous administration. As an example, chemotherapy administration, intravenous infusion technique, up to 1 hour, single or initial substance drug requires CPT code 96413 1

Please see Important Safety Information on pages 3 and 15-16 and full Prescribing Information for AVGEMSIT™.

FL 45**(Electronic Claim Form = Loop 2400, Segment DTP/472/03):**

Enter the date of service.

FL 46**(Electronic Claim Form = Loop 2400, SV205):**Enter the units for the HCPCS code billed.
Enter the number of service units for each item.**FL 63****(Electronic Claim Form = Loop 2300,REF/G1/02):**

Enter treatment authorization code.

FL 67A-Q**(Electronic Claim Form = Loop 2300, HI01-2 (HI01-1=BK)):**Enter a diagnosis code for the drug documented in the medical record. Be as specific as possible. The code listed here is an example: **C25.0 Malignant neoplasm of head of pancreas****FL 63****FL 67A-Q**

1	2	3a PAT CNT #	4 TYPE OF BILL				
		b. MED REC #					
		5 FED. TAX NO.	6 STATEMENT COVERS PERIOD FROM 7				
8 PATIENT NAME		9 PATIENT ADDRESS					
10 BIRTHDATE	11 SEX	12 DATE ADMISSION 13 HR 14 TYPE 15 SRS	16 DHR 17 STAT 18 19 20 21 22 23 24 25 26 27 28 29 ACCT 30 STATE				
31 OCCURRENCE DATE CODE	32 OCCURRENCE DATE CODE	33 OCCURRENCE DATE CODE	34 OCCURRENCE DATE CODE	35 OCCURRENCE SPAN FROM	36 OCCURRENCE SPAN FROM	37	
38	39 CODE VALUE CODES AMOUNT	40 CODE VALUE CODES AMOUNT	41 CODE VALUE CODES AMOUNT				
a	b	c					
42 REV CO.	43 DESCRIPTION	44 HCPCS / RATE / HRS	45 SERV. DATE	46 SERV. UNITS	47 TOTAL CHARGES	48 NON-COVERED CHARGES	49
1							1
2							2
3							3
4							4
5							5
6							6
7							7
8							8
9							9
10							10
11							11
12							12
13							13
14							14
15							15
16							16
17							17
18							18
19							19
20							20
21							21
22							22
23							23
24							
25							
26							
27							
28							
29							
30							
31							
32							
33							
34							
35							
36							
37							
38							
39							
40							
41							
42							
43							
44							
45							
46							
47							
48							
49							
50	PAYER NAME	51 HEALTH PLAN ID	52 REC. AMT	53 REC. AMT	54 PRIOR PAYMENTS	55 EST. AMOUNT DUE	56 NPI
A							57
B							OTHER
C							PRV ID
58	INSURED'S NAME	59 PTEL	60 INSURED'S UNIQUE ID	61 GROUP NAME	62 INSURANCE GROUP NO.		
A							
B							
C							
63	TREATMENT AUTHORIZATION CODES			64 DOCUMENT CONTROL NUMBER	65 EMPLOYER NAME		
A							
B							
66	C50.111						
67	68						
68							
69	ADMIT DX	70 PATIENT REASON DX	71 OTHER PROCEDURE CODE	72 EDI	73		
70							
71							
72							
73							
74	PRINCIPAL PROCEDURE CODE	OTHER PROCEDURE DATE	b. OTHER PROCEDURE CODE	75	76 ATTENDING NPI	77 OPERATING NPI	
75							
c. OTHER PROCEDURE DATE	d. OTHER PROCEDURE DATE	e. OTHER PROCEDURE DATE					
76							
77							
78	REMARKS	81CC a	81CC b	81CC c	78 OTHER NPI	79 OTHER NPI	
79							
80							
81							
82							
83							
84							
85							
86							
87							
88							
89							
90							
91							
92							
93							
94							
95							
96							
97							
98							
99							
100							
101							
102							
103							
104							
105							
106							
107							
108							
109							
110							
111							
112							
113							
114							
115							
116							
117							
118							
119							
120							
121							
122							
123							
124							
125							
126							
127							
128							
129							
130							
131							
132							
133							
134							
135							
136							
137							
138							
139							
140							
141							
142							
143							
144							
145							
146							
147							
148							
149							
150							
151							
152							
153							
154							
155							
156							
157							
158							
159							
160							
161							
162							
163							
164							
165							
166							
167							
168							
169							
170							
171							
172							
173							
174							
175							
176							
177							
178							
179							
180							
181							
182							
183							
184							
185							
186							
187							
188							
189							
190							
191							
192							
193							
194							
195							
196							
197							
198							
199							
200							
201							
202							
203							
204							
205							
206							
207							
208							
209							
210							
211							
212							
213							
214							
215							
216							
217							
218							
219							
220							
221							
222							
223							
224							
225							
226							
227							
228							
229							
230							
231							
232							
233							
234							
235							
236							
237							
238							
239							
240							
241							
242							
243							
244							
245							
246							
247							
248							
249							
250							

Sample Claim Form CMS-1500

Item 21

(Electronic Claim Form = Loop 2300, Segment H101-2 through H112=2):

Enter the patient's diagnosis from the patient's medical record. An example code for this drug is C25.0 Malignant neoplasm of head of pancreas. Use Box 21 B-L fields for secondary diagnoses.



HEALTH INSURANCE CLAIM FORM

APPROVED BY NATIONAL UNIFORM CLAIM COMMITTEE (NUCC) 02/12

PICA										PICA									
1. MEDICARE	MEDICAID	TRICARE	CHAMPVA	GROUP	HEALTH PLAN	FICA	BUKLUNG	OTHER	1a. INSURED'S I.D. NUMBER	(For Program in Item 1)									
<input type="checkbox"/> Medicare#	<input type="checkbox"/> Medicaid#	<input type="checkbox"/> DOD/DOD#	<input type="checkbox"/> Member ID#	<input type="checkbox"/> /ID#	<input type="checkbox"/> /ID#	<input type="checkbox"/> /ID#	<input type="checkbox"/> /ID#	<input type="checkbox"/> /ID#											
2. PATIENT'S NAME (Last Name, First Name, Middle Initial)					3. PATIENT'S BIRTH DATE					4. INSURED'S NAME (Last Name, First Name, Middle Initial)									
					MM	DD	YY	SEX											
					<input type="checkbox"/> M	<input type="checkbox"/> F													
5. PATIENT'S ADDRESS (No., Street)					6. PATIENT RELATIONSHIP TO INSURED					7. INSURED'S ADDRESS (No., Street)									
					<input type="checkbox"/> Self	<input type="checkbox"/> Spouse	<input type="checkbox"/> Child	<input type="checkbox"/> Other											
CITY		STATE			CITY		STATE												
ZIP CODE		TELEPHONE (Include Area Code)			ZIP CODE		TELEPHONE (Include Area Code)												
()		()																	
9. OTHER INSURED'S NAME (Last Name, First Name, Middle Initial)					10. IS PATIENT'S CONDITION RELATED TO:					11. INSURED'S POLICY GROUP OR FICA NUMBER									
					a. EMPLOYMENT? (Current or Previous) <input type="checkbox"/> YES <input type="checkbox"/> NO					a. INSURED'S DATE OF BIRTH MM DD YY									
					b. AUTO ACCIDENT? <input type="checkbox"/> YES <input type="checkbox"/> NO					b. OTHER CLAIM ID (Designated by NUCC)									
					c. OTHER ACCIDENT? <input type="checkbox"/> YES <input type="checkbox"/> NO					c. INSURANCE PLAN NAME OR PROGRAM NAME									
					10d. CLAIM CODES (Designated by NUCC)					d. IS THERE ANOTHER HEALTH BENEFIT PLAN?									
										d. YES <input type="checkbox"/> NO <input type="checkbox"/> If yes, complete items 9, 9a, and 9d.									
READ BACK OF FORM BEFORE COMPLETING & SIGNING THIS FORM.										13. INSURED'S OR AUTHORIZED PERSON'S SIGNATURE I authorize the release of any medical or other information necessary to process this claim. I also request payment of government benefits either to myself or to the party who accepts assignment below.									
14. DATE OF CURRENT ILLNESS, INJURY, or PREGNANCY (LMP) MM DD YY QUAL					15. OTHER DATE MM DD YY QUAL					16. DATES PATIENT UNABLE TO WORK IN CURRENT OCCUPATION FROM MM DD YY TO MM DD YY									
17. NAME OF REFERRING PROVIDER OR OTHER SOURCE 17a. _____ 17b. NPI _____					18. HOSPITALIZATION DATES RELATED TO CURRENT SERVICES FROM MM DD YY TO MM DD YY														
19. ADDITIONAL CLAIM INFORMATION (Designated by NUCC)					20. OUTSIDE LAB? \$ CHARGES <input type="checkbox"/> YES <input type="checkbox"/> NO														
21. DIAGNOSIS OR NATURE OF ILLNESS OR INJURY: Relate A-L to service line below (24E) ICD Ind. _____					22. RESUBMISSION CODE _____ ORIGINAL REF. NO. _____														
A. _____	B. _____	C. _____	D. _____	E. _____	F. _____	G. _____	H. _____	I. _____	J. _____	K. _____	L. _____	F. \$ CHARGES	G. CHARGES OR UNITS	H. PAYMENT METHOD	I. ID QUAL	J. RENDERING PROVIDER ID. #			
24. A. DATE(S) OF SERVICE From MM DD YY To MM DD YY					B. PROCEDURES, SERVICES, OR SUPPLIES (Specify Unusual Circumstances) CPT/HCPCS					C. MODIFIER									
25. FEDERAL TAX I.D. NUMBER SSN EIN					26. PATIENT'S ACCOUNT NO.					27. ACCEPT & ASSIGNMENT? (For Govt. claims, see back) <input type="checkbox"/> YES <input type="checkbox"/> NO					28. TOTAL CHARGE \$		29. AMOUNT PAID \$		30. Paid for NUCC Use _____
31. SIGNATURE OF PHYSICIAN OR SUPPLIER INCLUDING DEGREES OR CREDENTIALS (I certify that the statements on the reverse apply to this bill and are made a part thereof.)					32. SERVICE FACILITY LOCATION INFORMATION					33. BILLING PROVIDER INFO & PH# ()									
SIGNED _____ DATE _____					a. NPI b. _____					a. NPI b. _____									
PLEASE PRINT OR TYPE										APPROVED OMB:0938-1197 FORM 1500 (02-12)									

CARRIER

PATIENT AND INSURED INFORMATION

PHYSICIAN OR SUPPLIER INFORMATION

Item 21

(Electronic Claim Form = Loop 2300, REF02):

Enter prior authorization number if one exists.

Item 23

(Electronic Claim Form = Loop 2300, Segment SV02):

Enter the appropriate HCPCS code: J9184, Injection, gemcitabine hydrochloride (avyxa), 200 mg For administration, enter the appropriate code or codes for intravenous administration. As an example, chemotherapy administration, intravenous infusion technique, up to 1 hour, single or initial substance drug requires CPT code 96413.¹

Item 24D

Item 24D

(Electronic Claim Form = Loop 2400, Segment SV101):

Specify the diagnosis letter that corresponds with the drug and drug administration code(s) in Box 21.

Item 23

Item 24E

Item 24E

APPROVED OMB:0938-1197 FORM 1500 (02-12)

Item 24A-B

**(Electronic Claim Form:
Item 24A (Electronic Claims = Loop
2400, DTP02;
Item 24 B (Loop 2300/2400, Segment
CLM05-1/SV105))**

In the non-shaded area, enter the appropriate date of service and place of service code.

Example: Physician Office = 11.

If required, in the shaded area, enter the N4 indicator first, then the 11-digit NDC code. In the third space, list the NDC unit measurement code, and last, the quantity. The NDC Unit of Measurement for AVGEMSI™ is ML.

Item 24G

**(Electronic Claim Form = Loop
2400, SV104):**

Enter the number of service units for each item.

Item 24A-B

HEALTH INSURANCE CLAIM FORM
APPROVED BY NATIONAL UNIFORM CLAIM COMMITTEE (NUCC) 02/12

1. MEDICARE (Medicare#)	MEDICAID (Medicaid#)	TRICARE (TRICARE#)	CHAMPVA (Champva#)	GROUP HEALTH PLAN (Group#)	FECA BENEFITS (ID#)	OTHER (ID#)	1a. INSURED'S I.D. NUMBER (For Program in Item 1)	PICA (PICA#)	CARRIER (Carrier#)
2. PATIENT'S NAME (Last Name, First Name, Middle Initial)					3. PATIENT'S BIRTH DATE MM DD YY		4. INSURED'S NAME (Last Name, First Name, Middle Initial)		
					M F				
5. PATIENT'S ADDRESS (No., Street)					6. PATIENT RELATIONSHIP TO INSURED Self Spouse Child Other		7. INSURED'S ADDRESS (No., Street)		
CITY		STATE			8. RESERVED FOR NUCC USE		CITY		STATE
ZIP CODE		TELEPHONE (Include Area Code) ()					ZIP CODE		TELEPHONE (Include Area Code) ()
9. OTHER INSURED'S NAME (Last Name, First Name, Middle Initial)					10. IS PATIENT'S CONDITION RELATED TO:				
a. OTHER INSURED'S POLICY OR GROUP NUMBER					a. EMPLOYMENT? (Current or Previous) <input type="checkbox"/> YES <input type="checkbox"/> NO				
b. RESERVED FOR NUCC USE					b. AUTO ACCIDENT? <input type="checkbox"/> YES <input type="checkbox"/> NO PLACE (State)				
c. RESERVED FOR NUCC USE					c. OTHER ACCIDENT? <input type="checkbox"/> YES <input type="checkbox"/> NO				
d. INSURANCE PLAN NAME OR PROGRAM NAME					10d. CLAIM CODES (Designated by NUCC)				
12. PATIENT'S OR AUTHORIZED PERSON'S SIGNATURE I authorize the release of any medical or other information necessary to process this claim. I also request payment of government benefits either to myself or to the party who accepts assignment below.					11. INSURED'S POLICY GROUP OR FECA NUMBER				
SIGNED _____ DATE _____					a. INSURED'S DATE OF BIRTH MM DD YY M F				
14. DATE OF CURRENT ILLNESS, INJURY, or PREGNANCY (LMP) MM DD YY QUAL					b. OTHER CLAIM ID (Designated by NUCC)				
15. OTHER DATE MM DD YY					c. INSURANCE PLAN NAME OR PROGRAM NAME				
17. NAME OF REFERRING PROVIDER OR OTHER SOURCE 17a. _____ 17b. NPI _____					13. IS THERE ANOTHER HEALTH BENEFIT PLAN? <input type="checkbox"/> YES <input type="checkbox"/> NO If yes, complete items 9, 9a, and 9d.				
19. ADDITIONAL CLAIM INFORMATION (Designated by NUCC)					16. DATE PATIENT UNABLE TO WORK IN CURRENT OCCUPATION FROM MM DD YY TO MM DD YY				
21. DIAGNOSIS OR NATURE OF ILLNESS OR INJURY Relate A-L to service line below (24E) ICD Ind. _____					18. HOSPITALIZATION DATES RELATED TO CURRENT SERVICES FROM MM DD YY TO MM DD YY				
A. _____ B. _____ C. _____ D. _____ E. _____ F. _____ G. _____ H. _____ I. _____ J. _____ K. _____ L. _____					20. OUTSIDE LAB? \$ CHARGES <input type="checkbox"/> YES <input type="checkbox"/> NO				
24. A. DATE(S) OF SERVICE From MM DD YY To MM DD YY B. PLAC OF SERVICE EMG C. D. PROCEDURES, SERVICES, OR SUPPLIES (Enter Usual Circumstances) CPT/HCPCS MODIFIER					22. RESUBMISSION CODE _____ ORIGINAL REF. NO. _____				
E. DIAGNOSIS PONTER					23. PRIOR AUTHORIZATION NUMBER				
F. \$ CHARGES G. DAYS H. UNIT I. ID J. RENDERING PROVIDER ID #									
1 2 3 4 5 6					Item 24G				
25. FEDERAL TAX I.D. NUMBER SSN EIN					26. PATIENT'S ACCOUNT NO. 27. ACCEPT ASSIGNMENT? For govt claims, see back <input type="checkbox"/> YES <input type="checkbox"/> NO				
28. TOTAL CHARGE \$					29. AMOUNT PAID \$				
30. Rsd for NUCC Use					31. SIGNATURE OF PHYSICIAN OR SUPPLIER INCLUDING DEGREES OR CREDENTIALS (I certify that the statements on the reverse apply to this bill and are made a part hereof.)				
32. SERVICE FACILITY LOCATION INFORMATION a. NPI b. _____					33. BILLING PROVIDER INFO & PH# () a. NPI b. _____				

NUCC Instruction Manual available at: www.nucc.org PLEASE PRINT OR TYPE APPROVED OMB 0938-1197 FORM 1500 (02-12)

[1] CPT Code 96413 Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug. Initial infusion times may vary.

Electronic Claims Reference: ASC 837I Version 5010A2 Institutional Health Care Claim to the CMS-1450 Claim Form Crosswalk. Palmettoga.com. Palmetto GBA, Accessed April 3, 2023. [\\$File/EDI_837I_v5010A2_crosswalk.pdf](https://dominoapps.palmettoga.com/palmetto/providers.nsf/files/EDI_837I_v5010A2_crosswalk.pdf)

CPT Codes are a registered trademark of the American Medical Association (AMA), All Rights Reserved.

THIS INFORMATION IS PROVIDED FOR EDUCATIONAL PURPOSES ONLY AND IS NOT A GUARANTEE OF COVERAGE.

IT IS THE SOLE RESPONSIBILITY OF THE HEALTH CARE PROVIDER TO SELECT THE PROPER CODES AND ENSURE THE ACCURACY OF ALL STATEMENTS USED IN SEEKING COVERAGE AND REIMBURSEMENT FOR AN INDIVIDUAL PATIENT.

IMPORTANT SAFETY INFORMATION (CONTINUED)

Pulmonary Toxicity and Respiratory Failure: Pulmonary toxicity, including interstitial pneumonitis, pulmonary fibrosis, pulmonary edema, and adult respiratory distress syndrome (ARDS), has been reported. In some cases, these pulmonary events can lead to fatal respiratory failure despite the discontinuation of therapy. The onset of pulmonary symptoms may occur up to 2 weeks after the last dose of gemcitabine.

Permanently discontinue AVGEMSI in patients who develop unexplained dyspnea, with or without bronchospasm, or evidence of severe pulmonary toxicity.

Hemolytic Uremic Syndrome (HUS): HUS, including fatalities from renal failure or the requirement for dialysis, can occur with gemcitabine. In clinical trials, HUS occurred in 0.25% of 2429 patients. Most fatal cases of renal failure were due to HUS. Serious cases of thrombotic microangiopathy other than HUS have been reported with gemcitabine.

Assess renal function prior to initiation of AVGEMSI and periodically during treatment. Consider the diagnosis of HUS in patients who develop anemia with evidence of microangiopathic hemolysis; increased bilirubin or LDH; reticulocytosis; severe thrombocytopenia; or evidence of renal failure (increased serum creatinine or BUN).

Permanently discontinue AVGEMSI in patients with HUS or severe renal impairment. Renal failure may not be reversible even with the discontinuation of therapy.

Hepatic Toxicity: Drug-induced liver injury, including liver failure and death, has been reported in patients receiving gemcitabine alone or with other potentially hepatotoxic drugs. Administration of gemcitabine in patients with concurrent liver metastases or a pre-existing medical history of hepatitis, alcoholism, or liver cirrhosis can lead to exacerbation of the underlying hepatic insufficiency. Assess hepatic function prior to initiation of AVGEMSI and periodically during treatment. Permanently discontinue AVGEMSI in patients who develop severe hepatic toxicity.

Embryo-Fetal Toxicity: AVGEMSI can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with AVGEMSI and for 6 months after the final dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with AVGEMSI and for 3 months following the final dose.

Exacerbation of Radiation Therapy Toxicity: Gemcitabine is not recommended for use in combination with radiation therapy.

Concurrent (given together or ≤7 days apart)

Life-threatening mucositis, especially esophagitis and pneumonitis occurred in a trial in which gemcitabine was administered at a dose of 1000 mg/m² to patients with non-small cell lung cancer for up to 6 consecutive weeks concurrently with thoracic radiation.

Non-concurrent (given >7 days apart)

Excessive toxicity has not been observed when gemcitabine is administered more than 7 days before or after radiation. Radiation recall has been reported in patients who received gemcitabine after prior radiation.

Capillary Leak Syndrome (CLS): CLS with severe consequences has been reported in patients receiving gemcitabine as a single agent or in combination with other chemotherapeutic agents. Permanently discontinue AVGEMSI if CLS develops during therapy.

Posterior Reversible Encephalopathy Syndrome (PRES): PRES has been reported in patients receiving gemcitabine as a single agent or in combination with other chemotherapeutic agents. PRES can present with headache, seizure, lethargy, hypertension, confusion, blindness, and other visual and neurologic disturbances. Confirm the diagnosis of PRES with magnetic resonance imaging (MRI). Permanently discontinue AVGEMSI if PRES develops during therapy.

ADVERSE REACTIONS

The most common adverse reactions for the single agent ($\geq 20\%$) are nausea/vomiting, anemia, increased aspartate aminotransferase (AST), increased alanine aminotransferase (ALT), neutropenia, increased alkaline phosphatase, proteinuria, fever, hematuria, rash, thrombocytopenia, dyspnea, and edema.

USE IN SPECIFIC POPULATIONS

Pregnancy: Advise pregnant women of the potential risk to a fetus with AVGEMSI.

Lactation: Advise women not to breastfeed during treatment with AVGEMSI.

Females and Males of Reproductive Potential: Advise females and males of reproductive potential to use effective contraception during treatment with AVGEMSI.

OVERDOSAGE

There is no known antidote for overdoses of gemcitabine. Myelosuppression, paresthesias, and severe rash were the principal toxicities seen when a single dose as high as 5700 mg/m^2 was administered by intravenous infusion over 30 minutes every 2 weeks to several patients in a dose-escalation study. In the event of suspected overdose, monitor with appropriate blood counts and provide supportive therapy, as necessary.

To report SUSPECTED ADVERSE REACTIONS, contact Avyxa Pharma, LLC at 1-888-520-0954 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full [Prescribing Information](#) of AVGEMSI.

Notes

References:

1. AVYXA.™ AVGEMSI™ (gemcitabine) Injection, Full Prescribing Information. Section 16, How Supplied/Storage and Handling. Revised July 2025.
2. Centers for Medicare and Medicaid Services (2025, Nov. 10). Healthcare Common Procedure Coding System (HCPCS). CMS.gov. Retrieved July 16, 2025, from <https://www.cms.gov/medicare/coding-billing/healthcare-common-procedure-system>
3. AVYXA.™ AVGEMSI™ (gemcitabine) Injection, Full Prescribing Information. Section 1.4. Indications and Usage. Revised July 2025.
4. AVYXA.™ AVGEMSI™ (gemcitabine) Injection, Full Prescribing Information. Section 2.4. Dosage and Administration. Revised July 2025.
5. American Medical Association (2025, June 27). CPT® Overview and Code Approval. AMA.org. Retrieved July 17, 2025, from [https://www.ama-assn.org/practice-management/cpt/cpt-overview-and-code-approval#:~:text=The%20Current%20Procedural%20Terminology%20\(CPT,reporting%2C%20%20increase%20accuracy%20and%20efficiency](https://www.ama-assn.org/practice-management/cpt/cpt-overview-and-code-approval#:~:text=The%20Current%20Procedural%20Terminology%20(CPT,reporting%2C%20%20increase%20accuracy%20and%20efficiency)
6. AVYXA.™ AVGEMSI™ (gemcitabine) Injection, Full Prescribing Information. Section 2. Dosage and Administration. Revised July 2025
7. CMS. Billing and Coding: JW and JZ Modifier Billing Guidelines. Article ID A55932. Accessed January 27, 2025. <https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=55932>
8. CMS. Place of Service Code Set. Revised May 2, 2024. Accessed July 7, 2025. <https://www.cms.gov/medicare/coding-billing/place-of-service-codes/code-sets>
9. American Medical Association. (2024). 2025 AMA CPT Professional Edition. ISBN 978-1-64016-304-1. ISSN — 0276-8283. Medicine. Hydration, Therapeutic, Prophylactic, Diagnostic Injections and Infusions, and Chemotherapy and Other Highly Complex Biologic Agent Administration. CPT Code 96413. Page 869. Accessed July 17, 2025
10. American Medical Association. (2024). 2025 AMA CPT Professional Edition. ISBN 978-1-64016-304-1. ISSN 0276-8283. Medicine. Hydration, Therapeutic, Prophylactic, Diagnostic Injections and Infusions, and Chemotherapy and Other Highly Complex Biologic Agent Administration. CPT Code 96417. Page 869. Accessed July 17, 2025.
11. Noridian Healthcare Solutions. Revenue Codes. Pharmacy-Extension of 025X. Code 0636 Drugs requiring detailed coding. Updated March 18, 2024. Accessed July 17, 2025. <https://med.noridianmedicare.com/web/jfa/topics/claim-submission/revenue-codes>
12. Noridian Healthcare Solutions. Revenue Codes. Radiology Therapeutic and/or Chemotherapy Administration. Code 0335 – Chemotherapy Administration- IV. Updated March 18, 2024. Accessed July 17, 2025. <https://med.noridianmedicare.com/web/jfa/topics/claim-submission/revenue-codes>
13. AVYXA.™ AVGEMSI™ (gemcitabine) Injection, Full Prescribing Information. Section 1. Indications and Usage. Revised July 2025.
14. American Academy of Professional Coders (AAPC). (2024) 2025 ICD-10-CM Expert Edition. eBook ISBN 978-1-635277-494. Chapter 2: Neoplasms. Section Malignant Neoplasms of female genital organs (C51-C58). ICD-10-CM Code C56.1-C56.9. Pg 1036. Accessed July 17, 2025.
15. American Academy of Professional Coders (AAPC). (2024) 2025 ICD-10-CM Expert Edition. eBook ISBN 978-1-635277-494. Chapter 2: Neoplasms. Section Malignant Neoplasms of Breast (C50). ICD-10-CM Code C50.011-C50.929. Pg 1035. Accessed July 17, 2025.
16. American Academy of Professional Coders (AAPC). (2024) 2025 ICD-10-CM Expert Edition. eBook ISBN 978-1-635277-494. Chapter 2: Neoplasms. Section Malignant neoplasms of respiratory and intrathoracic organs (C30-C39). ICD-10-CM Code C33-C34.92) Pg 1027. Accessed July 17, 2025.
17. American Academy of Professional Coders (AAPC). (2024) 2025 ICD-10-CM Expert Edition. eBook ISBN 978-1-635277-494. Chapter 2: Neoplasms. Section Malignant neoplasms of digestive organs (C15-C26). ICD-10-CM Code C25.0-C25.9) Pg 1025. Accessed July 17, 2025.

